Topical triple-therapy of chronic stationary psoriasis (CSP). Increased healing effectiveness compared with a dithranol monotherapy

In a randomized, open and prospective study 30 patients (14 females and 16 males: average age 48.3 ± 17.3) with chronic-stationary psoriasis vulgaris were treated with three different combinations of topical drugs according to the following protocol. Three different groups were made up: Group 1 (n = 10, initial PASI 18,9) received a combination of mometason (mornings) - dithranol (at noon) - tazaroten 0.025% (evenings) (MDT), group 2 (n = 10, PASI 18.1) urea (mornings) -dithranol (at noon) - tazaroten 0.025% (evenings) (UDT) and group 3 (n = 10, initial PASI 18.8) calcipotriol (mornings) - dithranol (at noon) - tazaroten 0.025% (evenings) (CDT). During the therapy period of 4 weeks we documented the PASI-Score, infiltration, erythema, desquamation and perilesional irritation. 25 patients of 30 fulfilled the protocol, 5 patients had to drop out because of irritations (3xUDT; 1xMDT; 1xCDT). The collectives CDT (

PASI:

18.8-1.9) and MDT (

PASI:

18.9-2.0) revealed a significantly faster reduction of the PASI as the UDT collective (

PASI:

18.1-3.1). Lokal irritations in the CDT and MDT groups occurred less often than in the collective UDT. There were no dithranol-hyperpigmentations in any collective. In comparison to former studies (1995; n = 30; classic dithranol-monotherapy) the time of therapy was reduced from 28.5 to 19.5 days in the collectives (MDT; CDT). That leads to an enormous potential for saving costs.